CAMBRIDGE, MA, AND PARIS, FRANCE, November 7, 2016 – HiFiBiO SAS today announced that the latest results from their CelliGO™ platform will be presented by Senior Scientists and Project Leaders, Dr Adam Woolfe and Dr. Marcel Reichen as part of the 2016 Human Antibodies and Hybridomas Conference. The presentations will feature the latest achievements in deep mining human and rodent immune repertoires for therapeutic antibody discovery and deep mining approaches to addressing challenging targets such as cell surface targets using in-droplet functional assays.
Presentation Title 1: ‘CelliGO™ discovery of therapeutic antibodies for challenging targets using single-B-cell screening by nano-droplet microfluidics’ . The presentation, will be on Wednesday, Nov. 9 at 12:00 GMT.
Presentation Title 2: ‘Functional therapeutic antibody hits to challenging targets using the CelliGO ™ platform’ . The presentation, will be on Wednesday, Nov. 9 at 16:55 GMT.
HiFiBiO’s platform employs paired bar coding, next generation sequencing and rapid DNA synthesis coupled to high throughput cloning and expression enabling single cell-based screening of entire antibody-secreting B cell populations. Identification of diverse high quality leads is expected to lower the risk of developing optimized antibody drug candidates. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Learn more at www.hifibio.com.